- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03662763
Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity (SPD503-315)
September 6, 2018 updated by: Maastricht University Medical Center
Phase 3,Double Blind,Placebo-controlled,Multicentre,Randomised-withdrawal,Long-term Maintenance of Efficacy&Safety Study of Extended-release Guanfacine Hydrochloride in Children/Adolescents Aged 6-17 With ADHD
A study to evaluate the long term maintenance of efficacy of using Guanfacine Hydrochloride (SPD-503) for the treatment of ADHD in Children aged 6-17 years in Europe, Australia, Canada and the US.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The SPD503-315 clinical program has studied the efficacy, safety, and tolerability of this product in treating symptoms of ADHD in children and adolescents aged 6-17 through short-term, placebo-controlled studies and long-termn, open-label studies.
This study will more rigorously assess the long-term maintenance of efficacy using a placebo-controlled, randomised-withdrawal design.
To date, all of the completed studies conducted as part of the SPD503 proigram have enrolled subjects from the US.
This study is designed to evaluate the long-term maintenance of efficacy of SPD503 for the treatment of ADHD in children aged 6-17 years in Europe, Australia, Canada and US.
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Maastricht, Netherlands
- Maastricht University Medical Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 17 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- male or female, aged 6-17 years at the time of consent/assent at Screening/Visit 1
- subject meets DSM-IV-TR criteria for primaru diagnosis of ADHD
- subject has a minimum ADHD-RS-IV total score of 32 at enrolment/visit 2
- subject has a minimum CGI-S score of 4 at Enrolment/Visit 2
- subject is able to swallow intact tablets
Exclusion Criteria:
- subject has a current controlled or uncontrolled, co-morbid psychiatric diagnosis.
- subject has a know history or presence of structural cardiac abnormalities
- subject with orthostatic hyupotension or a known history of controlled or uncontrolled hypertension
- current use of any prohibited medication or other medications, including herbal supplements that affet blood pressure, or heart rate or that have CNS effects or affect cognitive performance
- subject is significant overweight based on Centre for disease control and prevention BMI for age gender specific charts. Significantly overweight is defined as a BMI >95 th percentile Children aged 6-12 years with a body weight ,25,0kg, or adolescents aged 13-17 years with a body weight <43 kg or >91 kg at screening/visit 1
- subject is currently considered a suicide risk in the opinion of the investigator
- history of failure to respond to an adequate trial of an alfa2-agonist for the treatment of ADHD.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
|
Experimental: Extended-release Guanfacine Hydrochloride (SPD503)
|
dosing in all subjects will initiate with 1mg/day, and may be increased by 1 mg increments after a minimum of 1 week on the current dose to the maximum doses based on age and weight.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Attention Deficit Hyperactivity Disorder-Rating Scale -IV
Time Frame: 13 weeks
|
13 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Clinical Global Impressions-Severity score
Time Frame: 13 weeks
|
13 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Andries Korebrits, prof. Dr., Psychiatrie
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2011
Primary Completion (Actual)
August 1, 2013
Study Completion (Actual)
December 1, 2013
Study Registration Dates
First Submitted
August 9, 2011
First Submitted That Met QC Criteria
September 6, 2018
First Posted (Actual)
September 7, 2018
Study Record Updates
Last Update Posted (Actual)
September 7, 2018
Last Update Submitted That Met QC Criteria
September 6, 2018
Last Verified
September 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Attention Deficit and Disruptive Behavior Disorders
- Neurodevelopmental Disorders
- Attention Deficit Disorder with Hyperactivity
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Guanfacine
Other Study ID Numbers
- 101081
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Attention Deficit Disorder
-
Cingulate TherapeuticsRecruitingPhase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301ADHD | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Ornit CohenUnknownAttention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | Attention Deficit Disorder | Attention Deficit Disorders With Hyperactivity | Attention Deficit Hyperactivity DisordersIsrael
-
University of PennsylvaniaNational Institutes of Health (NIH)TerminatedAttention Deficit Hyperactivity Disorder | Attention Deficit Disorder | Working MemoryUnited States
-
National Institute on Alcohol Abuse and Alcoholism...TerminatedAttention Deficit Disorder | Attention Deficit Hyerpactivity DisorderUnited States
-
Children's National Research InstituteRecruitingADHD | Attention Deficit Hyperactivity Disorder | Attention-Deficit Hyperactivity Disorder | Attention Deficit Disorder | ADD | ADHD Predominantly Inattentive Type | ADHD - Combined Type | ADHD, Predominantly Hyperactive - Impulsive | Attention-Deficit Disorder in Adolescence | Attention-Deficit Hyperactivity...United States
-
Sheba Medical CenterWithdrawnAttention Deficit Disorder With Hyperactivity | Attention-Deficit Disorder in Adolescence
-
Soroka University Medical CenterUnknownAttention Deficit Disorder PatientsIsrael
-
Tel-Aviv Sourasky Medical CenterElMindA Ltd; Brainsway; Ornim Medical Ltd.UnknownAdult Attention Deficit DisorderIsrael
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAttention Deficit Hyperactivity Disorder | Attention Deficit DisorderUnited States
-
Otsuka Pharmaceutical Development & Commercialization...CompletedAttention Deficit Hyperactivity Disorder | Attention Deficit DisorderUnited States
Clinical Trials on Placebo oral capsule
-
Sao Thai Duong Joint Stock CompanyBig Leap Clinical Research Joint Stock CompanyCompleted
-
Brigham and Women's HospitalCompleted
-
Georgetown UniversityNational Institutes of Health (NIH)RecruitingDementia With Lewy BodiesUnited States
-
Aelis FarmaNational Institute on Drug Abuse (NIDA)CompletedHealthy VolunteersUnited States
-
Brigham and Women's HospitalEnrolling by invitation
-
EicOsis Human Health Inc.National Institute of Neurological Disorders and Stroke (NINDS)CompletedHealthy AdultsUnited States
-
Brigham and Women's HospitalCompleted
-
Yale UniversityNeurocrine BiosciencesRecruitingTrichotillomania (Hair-Pulling Disorder)United States
-
Alkermes, Inc.Terminated
-
InFlectis BioScienceAssistance Publique Hopitaux De Marseille; Qualissima; Eurofins Optimed; Stragen...Completed